Heptanoic acid, 2,7-diamino-7-oxo-, (S)- | 26630-56-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Heptanoic acid, 2,7-diamino-7-oxo-, (S)-
• 英文别名: (2S)-2,7-diamino-7-oxoheptanoic acid
• CAS: 26630-56-8
• 化学式: C₇H₁₄N₂O₃
• 分子量: 174.2
• InChiKey: QTNACZLPTBPOOG-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.3
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit
  申请人：Van Venrooij Wilhelmus Waltherus Jacobus

  公开号：US20070087380A1

  公开（公告）日：2007-04-19

  The invention relates to method of detecting autoantibodies from patients suffering from rheumatoid arthritis. To this end, according to the invention, at least two peptide units are used of which at least one peptide unit comprises a part not derived from (pro)fillaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 and cytokeratin 9, and which peptide unit comprises the motif XG, and a peptide unit comprising the motif XnonG, wherein X is a citrullin or an analogue thereof, and nonG is an amino acid other than glycine.
• METHOD OF DETECTING AUTO-ANTIBODIES FROM PATIENTS SUFFERING FROM RHEUMATOID ARTHRITIS, A PEPTIDE AND AN ASSAY KIT
  申请人：VAN VENROOIJ Waltherus Jacobus Wilhelmus

  公开号：US20110195861A1

  公开（公告）日：2011-08-11

  A liposomal composition, preferably a vaccine, comprising liposomes formed of liposome forming compounds, containing coentrapped polysaccharide antigen and T-cell dependent protein carrier, such as tetanus toxoid or diphtheria toxin modified to render it non-toxic. The invention is of use in the production of vaccines against Haemophilus influenzae, Streptococcus pneumoniae or Neisseria meningitidis.
• PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF
  申请人：Lee Ho Huat

  公开号：US20160279261A1

  公开（公告）日：2016-09-29

  This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
• CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF
  申请人：3B PHARMACEUTICALS GMBH

  公开号：US20170119913A1

  公开（公告）日：2017-05-04

  The present invention is related to a conjugate comprising a structure of general formula (1) [TM1]-[AD1]-[LM]-[AD2]-[TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R 1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9 carboxylic acid; R 2 is selected from the group consisting of (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 3 C 8 )cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK′ is (C 2 -C 5 )alkylidene; R 3 , R 4 and R 5 are each and independently selected from the group consisting of hydrogen and (C 1 -C 4 )alkyl under the proviso that one of R 3 , R 4 and R 5 is of the following formula (3) wherein ALK′ is (C 2 -C 5 )alkylidene; R 6 is selected from the (2) group consisting of hydrogen and (C 1 -C 4 )alkyl; and R 7 is a bond; or a pharmacologically acceptable salt, solvate or hydrate thereof.
• US7888133B2
  申请人：——

  公开号：US7888133B2

  公开（公告）日：2011-02-15